NBY vs RARE · $51.9M cap vs rev $350.0M
NovaBay Pharmaceuticals Inc (NBY) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
NovaBay Pharmaceuticals Inc (NBY) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
NBY does not have a complete income-statement cache yet.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
NBY currently screens at market cap $51.9M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the NBY and RARE stock pages for the full models.
Not investment advice.